

For Immediate Release

For More Information:

Molly Varnau
Front Line Strategic Consulting, Inc.
650-525-1500 x102
molly@frontlinesmc.com

COMBINATION PRODUCTS MARKET EXPANDING THROUGH 2009
Therapeutic and Medical Device Companies Looking to Collaborate

November 19, 2003, San Mateo, California – With the generation of the Office of Combination Products in the FDA in December 2002, approval times for combination products are being reduced. For this reason, device companies are amplifying their efforts to improve upon existing medical devices and using new technologies to solve problems that limit physicians' ability to treat patients. In the report, *Combination Products: An Impact Analysis on the Convergence of Medical Devices and Therapeutics*, Front Line Strategic Consulting, Inc. has encapsulated the world of medical devices and therapeutics and identified the financial potential linked to satisfying unmet needs with the convergence of these products.

The global market for combination products is expanding, with companies; such as Medtronic, Abbott Vascular, and Genzyme; creating innovative technologies that will potentially render several current medical devices obsolete. Drug-eluting stents are projected to account for approximately 70% of the combination products market in 2009. Other future combination products include bioartificial pancreases, closed-loop glucose monitor/insulin pumps, and catheter-based suction devices with clot-dissolving enzymes.

According to Front Line's research and analysis, the worldwide combination products market will reach nearly \$6B in 2004 and nearly \$10B in 2009, driven by the shorter approval process and the need for improved medical devices. Companies planning to enter this market should establish collaborative relationships with the FDA, physicians, and third-party payers early in the development process. "It is essential that device companies conduct a rigorous analysis of the market potential and investigate all possible therapeutic candidates prior to developing a combination product. With a clear market positioning and development strategy, companies can significantly increase their chances of success," says Julie Watts, analyst, Strategic Market Reports division for Front Line.

About Front Line

Headquartered in San Mateo, California, Front Line is a leader in strategic consulting and market analysis for the Life Sciences industries, offering strategic business intelligence through exclusive consulting engagements and comprehensive strategic market reports of key therapeutic and technology areas. Front Line was founded in 1992 and specializes in combining diligent research methodology with intelligent strategic planning for their pharmaceutical and biotechnology customers. www.frontlinesmc.com

###